NEW DELHI: The pharma and healthcare sector witnessed a big 15% decline in quantity within the first quarter this yr, with 47 offers amounting to $ 409 million, as towards the earlier quarter, and an 82% lower in worth, in comparison with $2.3 billion in This autumn 2023. The common deal measurement this quarter declined by 79% at $8.7 million year-on-year, the Pharma and Healthcare Q1 Dealtracker report from Grant Thornton Bharat mentioned.
In Q1, there was a big lower in values primarily as a result of absence of big-ticket transactions, with just one high-value deal (over $100 million) recorded, contrasting with This autumn 2023, which noticed six such offers.
Medical gadgets and wellness area attracted buyers’ consideration, whereas the well being tech phase continued to garner larger volumes in offers.
Investor curiosity will proceed in biosimilar and API segments within the life sciences sector, and we might even see consolidation within the hospitals phase, it added.
Mergers and acquisitions (M&A) exercise additionally skilled a big decline each in quantity and worth in comparison with the earlier quarter. Volumes decreased by 54%, with solely 11 offers in Q1 2024, in comparison with 24 offers in This autumn 2023.
The highest two M&A offers have been Eric Lifesciences’ acquisition of Biocon Biologics valued at $150 million, whereas the opposite was Eris Lifesciences buy of a controlling stake in Swiss Parenterals at $77 million.
In Q1, there was a big lower in values primarily as a result of absence of big-ticket transactions, with just one high-value deal (over $100 million) recorded, contrasting with This autumn 2023, which noticed six such offers.
Medical gadgets and wellness area attracted buyers’ consideration, whereas the well being tech phase continued to garner larger volumes in offers.
Investor curiosity will proceed in biosimilar and API segments within the life sciences sector, and we might even see consolidation within the hospitals phase, it added.
Mergers and acquisitions (M&A) exercise additionally skilled a big decline each in quantity and worth in comparison with the earlier quarter. Volumes decreased by 54%, with solely 11 offers in Q1 2024, in comparison with 24 offers in This autumn 2023.
The highest two M&A offers have been Eric Lifesciences’ acquisition of Biocon Biologics valued at $150 million, whereas the opposite was Eris Lifesciences buy of a controlling stake in Swiss Parenterals at $77 million.
